Comparative Pharmacology
Head-to-head clinical analysis: FLUOCINONIDE versus LOCOID LIPOCREAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOCINONIDE versus LOCOID LIPOCREAM.
FLUOCINONIDE vs LOCOID LIPOCREAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinonide is a potent corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced prostaglandin and leukotriene synthesis. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Locoid Lipocream contains hydrocortisone butyrate, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, reduces mast cell degranulation, and decreases vascular permeability.
Topical: Apply a thin film to affected area 1-3 times daily. Limitation of use: Should not exceed 60 g per week in adults.
Apply a thin layer to affected area twice daily. Maximum duration of continuous treatment: 4 weeks.
None Documented
None Documented
Clinical Note
moderateFluocinonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Gatifloxacin."
Clinical Note
moderateFluocinonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Rosoxacin."
Clinical Note
moderateFluocinonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 1.3-2.4 hours in plasma. Clinically, due to high tissue binding and slow release from skin, the pharmacodynamic half-life for topical effect may extend to 12-24 hours.
Terminal elimination half-life: ~6-8 hours (hydrocortisone butyrate); clinical context: supports twice-daily dosing
Primarily hepatic metabolism; inactive metabolites excreted renally and fecally. Renal elimination accounts for approximately 60-70% of total clearance, fecal elimination ~30-40%. Less than 1% excreted unchanged in urine.
Renal: ~1.5% as unchanged hydrocortisone butyrate and metabolites; Biliary/fecal: ~85% as metabolites
Category A/B
Category C
Topical Corticosteroid
Topical Corticosteroid
Fluocinonide + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluocinonide is combined with Trovafloxacin."